Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.

Affiliation auteurs!!!! Error affiliation !!!!
TitreAvelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
Type de publicationJournal Article
Year of Publication2016
AuteursReck M, DeGreen HP, Rose AL, Pavlakis N, Derjcke SMaria, Radic J, Jeppesen N, Thomas M, Losonczy G, Kalinka-Warzocha E, Dreosti LMary, Ozguroglu M, Postmus PE, Helwig C, Chand V, Cuillerot J-M, Westeel V
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume34
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2016.34.15_suppl.TPS9105